Fierce Healthcare October 21, 2021
The Food and Drug Administration has contracted with real-world evidence company Aetion to use their platform for the assessment of COVID-19 inpatient medical products, the company announced today.
The Aetion Evidence Platform, which analyzes real-world data (RWD) pulled from electronic health records and medical claims, will enable the FDA to assess inpatient COVID-19 treatments in real-time.
“As part of this agreement, they’ll be able to apply the best practice science to different real-world data sources that are fit for the purpose of understanding inpatient treatments, learn to do this themselves and be able to apply it now or to other questions that emerge in the future,” said Jeremy Rassen, Sc.D., co-founder of Aetion, in an interview with Fierce Healthcare.
Aetion’s...